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Abstract
Background: The MHC and KIR loci are clinically relevant regions of the genome. Typing the sequence of these
loci has a wide range of applications including organ transplantation, drug discovery, pharmacogenomics and
furthering fundamental research in immune genetics. Rapid advances in biochemical and next-generation sequencing
(NGS) technologies have enabled several strategies for precise genotyping and phasing of candidate HLA alleles.
Nonetheless, as typing of candidate HLA alleles alone reveals limited aspects of the genetics of MHC region, it is
insufficient for the comprehensive utility of the aforementioned applications. For this reason, we believe phasing the
entire MHC and KIR locus onto a single locus-spanning haplotype can be a critical improvement for better
understanding transplantation biology.
Results: Generating long-range (>1 Mb) phase information is traditionally very challenging. As proximity-ligation based
methods of DNA sequencing preserves chromosome-span phase information, we have utilized this principle to
demonstrate its utility towards generating full-length phasing of MHC and KIR loci in human samples. We accurately
(~99 %) reconstruct the complete haplotypes for over 90 % of sequence variants (coding and non-coding) within
these two loci that collectively span 4-megabases.
Conclusions: By haplotyping a majority of coding and non-coding alleles at the MHC and KIR loci in a single assay, this
method has the potential to assist transplantation matching and facilitate investigation of the genetic basis of human
immunity and disease.
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Background
The major histocompatibility complex (MHC) and the
killer cell immunoglobulin-like receptor (KIR) are im-
portant regulators of human immune responses and are
involved in many human diseases [1, 2]. These loci are
highly polymorphic, allowing an extensive antigen-
presenting repertoire that enables strong immunity
against a wide range of foreign antigens, pathogens and
tumor cells [1–3]. At the same time, its immunogenic
heterogeneity can also create incompatibility in allotrans-
plantation procedures, causing graft rejections and graft-
versus-host disease (GVHD) [4, 5]. Furthermore, many of
the hundreds of genes within these immunogenic loci are
increasingly recognized as major susceptibility genes for
drug hypersensitivity reactions and appear to play a
significant role in numerous diseases, including cancer
[6–8]. Taken together, the clinical implications of these
loci make it useful to determine the sequence type of these
molecules.
Typing of human leukocyte antigen (HLA) genes, lo-
cated within the MHC locus, has traditionally been
achieved in low resolution using serotyping techniques
[9]. With advancements in technologies including PCR
and more recently, next generation DNA sequencing
(NGS), molecular-based methods have now enabled
more clinically significant high-resolution HLA typing
[10–12]. Notably, single-molecule NGS-based DNA se-
quencing has been demonstrated to resolve allele ambi-
guity by generating haplotypes of entire genes,
resulting in super high-resolution (8-digit) haplotyping
of HLA genes [13, 14]. However, even precise gene-
level haplotyping may not be sufficient for many
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applications. For example, while gene-level haplotyping
for several candidate HLA genes can reduce risk of graft
failure in transplantation matching, recipients could still
be susceptible to graft-versus-host disease, as the totality
of transplantation associated genes have not been fully
understood. In particular, reports suggest that non-HLA
gene families such as inflammatory genes, immune recep-
tors, or others across the MHC or KIR haplotype can
contribute to transplantation biology [15–17]. In addition,
the strong linkage disequilibrium (LD) patterns across the
MHC and KIR loci can allow coordinated functional activ-
ities of alleles on the same haplotype, complicating our
understanding of transplantation biology [4, 5, 9, 18, 19].
Indeed, knowledge of haplotypes across several HLA
genes has been shown to generate improved transplant-
ation outcome predictions [19, 20] and can therefore fa-
cilitate determination of novel haplotype patterns for drug
discovery and genome-wide association studies [21]. In
summary, it appears useful to haplotype the entirety of the
MHC and KIR loci to enable better understanding of
immune genetics through analyses of compound hetero-
zygous alleles.
Several experimental protocols have been developed to
construct long-range haplotypes. Specifically, methods
have been developed to generate mega-base-sized haplo-
types [22–25], while others can phase the entire chromo-
some [26–29]. However, the adaptability of these methods
to generate user-defined targeted haplotypes is unclear.
More recently, Targeted Locus Amplification (TLA) has
been developed to accomplish targeted phasing [30], but
as the haplotypes from TLA are limited to a few-hundred
kilobases, they may not be amenable for phasing large
mega-base scale loci such as the MHC. Here, we develop
a method, referred to as targeted HaploSeq, to generate
full-length complete haplotypes of MHC and KIR loci
from a single assay. Specifically, targeted HaploSeq com-
bines the previously published HaploSeq [26] method
developed for genome-wide haplotype phasing, with
oligo capture and sequencing. As a proof of principle,
we have applied targeted HaploSeq to the MHC and
KIR loci in human lymphoblastoid cells. We phased
over 90 % of the alleles in MHC and KIR loci at an esti-
mated accuracy of ~99 %. To our knowledge, targeted
HaploSeq is the first method to phase the MHC and
KIR loci into a single haplotype structure. These results
establish the utility of targeted HaploSeq for MHC and




In the targeted HaploSeq method, a conventional Hi-C li-
brary [31] is generated using HindIII restriction digestion
and amplified to obtain suitable material for oligonucleotide
probe-based enrichment of the target loci (Fig. 1a).
Briefly, based on simulation results (Additional file 1:
Fig. S1), we computationally generated the probe se-
quences, at 4X tiling density, using the SureDesign
Software (Agilent Technologies) and targeted the non-
repetitive +/− 400 bp regions adjacent to HindIII cut
sites over the MHC and KIR loci (Fig. 1b, Additional
file 2: Fig. S2a). In addition, to facilitate better phasing
of genic regions, we designed probes across the exons
within the MHC locus (Fig. 1a).
Next, by performing capture-sequencing [32, 33], we
generated targeted HaploSeq data in GM12878 lym-
phoblastoid cells at 2× whole-genome sequencing
depth with 30–50 fold target enrichment across the
MHC and KIR loci (Fig. 2a, Additional file 2: Fig. S2b).
More than 90 % of probes had at least 5-fold sequence
coverage compared to data from virtual probes with
an average of ~100 fold enrichment. This highlights
the sensitivity of the probes from our targeted Haplo-
Seq protocol. Next, to validate the quality of our tar-
geted HaploSeq data, we compared it to a previously
published HaploSeq dataset [26] generated from the
same cell line. As HaploSeq utilizes chromatin inter-
action patterns to reconstruct haplotypes, we com-
pared these between the two datasets and observed a
high concordance (r2 = 0.8, Fig. 2b, Additional file 3:
Fig. S3a, b). By using haplotype inference from the
parent–child trio whole-genome sequencing (WGS)
data [34], we examined the fraction of chromatin in-
teractions between the homologous chromosomes (h-
trans interactions), whose rarity is critical for accurate
de novo haplotyping. Similar to HaploSeq, targeted
HaploSeq data rarely exhibit h-trans interactions
(Additional file 4: Fig. S4a).
Of note, the MHC locus appears to have a higher h-
trans ratio in both HaploSeq and targeted HaploSeq
datasets, but several lines of evidence suggest that these
might be systematic errors from sequencing and ana-
lysis protocols. First, reads supporting h-trans interac-
tions are primarily observed in complex regions with
high variant density (Additional file 4: Fig. S4b). Sec-
ond, >85 % of h-trans interactions from targeted Haplo-
Seq dataset originate from the same end of a given
paired-end fragment. Lastly, about 95 % of these same-
end h-trans interactions are also observed in long-
fragment reads (LFR) in previously published Moleculo
datasets [25] from the same individual, indicating that a
significant fraction of these h-trans interactions could
have arisen from incorrect local haplotype inferences
from the parent-child trio WGS data (Fig. 2c, d,
Additional file 5). Taken together, our targeted Haplo-
Seq data is of high quality and therefore enables accur-
ate analyses of haplotype structures across the MHC
and KIR loci.
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High-resolution and accurate phasing of MHC and KIR loci
By utilizing heterozygous genotype identifications (SNVs)
from the trio-based WGS data [34], we used the HaploSeq
and LCP protocols to perform de novo haplotyping. We
generated a single haplotype structure over the MHC
locus resolving over 90 % of ~9,400 heterozygous alleles
and we used the trio-based haplotype structure to
estimate the accuracy of our approach to be ~97.7 %
(Additional file 6: Fig. S5). However, as the parent-child
trio data could have accumulated incorrect phasing at re-
gions with high variant density, we repeated the de novo
haplotyping protocol after ignoring variants that we found
to be h-trans in both our and LFR datasets. Consequently,
our phasing accuracy improved to 98.94 % (Additional
file 6: Fig. S5). Despite reducing the phasing error by over
50 %, from 2.3 to 1.06 %, we still observe a majority of
phasing errors occurring in the high variant density re-
gions (Fig. 2e). This suggests that the accuracy can poten-
tially be further improved by using long-read or single
molecule technologies that may be more suitable for map-
ping such complex regions. Of note, unlike switch
errors—the standard method to calculate phasing error
rates where an incorrect haplotype block is penalized only
once, we estimate error by testing each variant independ-
ently and therefore our error rate represents worst-case
scenario. To this end, as the density of variants affects the
resolution of HaploSeq-based haplotyping, we observed a
relatively lower resolution phasing for the KIR locus
(Additional file 1: Fig. S1b). Regardless, we obtained accur-
ate phasing of 348 out of 353 variants resolved at the KIR
Fig. 1 Targeted HaploSeq experimental design. a Outline of the Targeted HaploSeq protocol. Briefly, crosslinked chromatin is digested using restriction
enzyme(s) of choice. The digested chromatin ends are biotinylated and ligated in a spatially proximal manner, enabling formation of signature artificial
fragments—where spatially proximal distinct chromatin segments are combined into a single fragment. Target-specific oligonucleotide probes are then
used to capture and enrich for user-defined proximity-ligated artificial fragments, to create a targeted HaploSeq library. This library is sequenced and used
to generate locus-spanning haplotypes. b Illustration of oligonucleotide probe design: A browser shot of the 3.5 Mb MHC region illustrating location of
probes near HindIII cut sites. The inset shows probe targets near HLA-A gene. Specifically, we tiled 120 nt probes (blue) at 4X density across non-repetitive
segments around HindIII cut sites. In addition, we also targeted exonic regions of the MHC locus, as depicted in yellow
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Fig. 2 (See legend on next page.)
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loci (Fig. 2f ). Together, we resolved ~90 % of alleles
among the MHC and KIR loci at ~99 % accuracy
(Additional file 4: Fig. S4), demonstrating that our
approach can generate complete, high-resolution and
accurate haplotypes.
As current HLA typing protocols primarily type candi-
date genes across the MHC loci, we analyzed our
method’s phasing capabilities across heterozygous genes
from MHC and KIR loci. In total, we resolve ~92 % of
heterozygous variants, representing over 92 % of hetero-
zygous genes, at an accuracy of 99.34 % (Fig. 2e, f,
Additional file 7: Fig. S6). In this regard, we generate
highly accurate phasing for several “classical” genes used
in conventional HLA typing protocols. For example, in
the case of genes such as HLA-B, HLA-C, HLA-DRB1,
HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB1,
we resolve phasing of >99.5 % of the heterozygous vari-
ants at 100 % accuracy. Similarly at the KIR loci, we ac-
curately predict all but one exonic variant (Additional
file 7: Fig. S6). To our knowledge, our method is the first
to demonstrate high-resolution and accurate haplotyping
across the entire MHC and KIR loci, phasing not only
the highly diverse major and minor alleles, but also other
important immunological genes and variants at non-
genic regions across the locus together in a single haplo-
type structure.
Conclusions
Here, we describe the targeted HaploSeq method to gen-
erate large mega-base scale haplotypes in human cells.
Using this technology, we reconstruct complete phase
information of MHC and KIR loci. In principle, targeted
HaploSeq is blind to genotyping and can be used to
identify genetic variants de novo within the targeted loci.
For example at the MHC locus, our method identified
~27 % of variants at an accuracy of 99.76 and 89.21 %
for heterozygous and homozygous genotypes, respect-
ively. This performance can be further improved with
the use of multiple 4-base or 6-base cutters during Hi-C
library preparation [35], instead of a single 6-base recog-
nizing restriction enzyme as demonstrated in this manu-
script. Alternatively, computational strategies such as
population-based imputation can be also be used to gen-
erate comprehensive genotyping [36].
High-resolution genotyping and phasing of immuno-
genic loci such as MHC and KIR has several applications.
First, it has the potential to greatly improve the practice of
HLA typing/matching for clinical transplantation proce-
dures [13, 15, 20, 37], as this method provides access to
alleles that are otherwise un-typed using current methods.
In addition, with population-scale MHC and KIR haplo-
typing, our method can help to elucidate a refined set of
minimal alleles that confer the highest risk for GVHD,
thereby informing follow-up cost-effective selective typing
of these most informative alleles. Second, as our method
phases coding and non-coding cis-regulatory sequences
together, one can study patterns of compound heterozy-
gosity and linkage of human immune variation [7, 16, 17].
Finally, several studies have uncovered numerous
disease-associated HLA and KIR alleles and by under-
standing long-range haplotypes, we can now start to
unravel mechanistic underpinnings of human immune
disorders [21, 38, 39].
Recently, proximity-ligation methods such as Hi-C
have been demonstrated to be useful in assembling ge-
nomes de novo [40, 41]. As targeted HaploSeq obtains
high-quality chromatin interaction datasets, similar to
Hi-C [31], this methodology can potentially be used to
generate diploid assembly of complex regions, such as
the MHC or T-cell receptor beta (Tcrb) locus [42], of
human and other large genomes. Similarly, Hi-C has
also recently been used in metagenomics studies to
deconvolute the species present in complex micro-
biome mixtures [43, 44]. With the advent of targeted
HaploSeq, it is now possible to capture distinct loci that
are informative and discriminative enough to delineate
species mixtures based on the captured proximity-
ligation fragments.
(See figure on previous page.)
Fig. 2 High-resolution and accurate phasing of MHC and KIR loci. a (i) Top chart demonstrates enrichment of targeted HaploSeq reads at the
100 kb binned MHC locus and the bottom plot shows number of probes in 100 kb bins used across the MHC locus. Visually, we can observe a
high correlation between these plots, demonstrating the expected relationship between density of probes and the sequencing depth of targeted
HaploSeq reads. (ii) To illustrate the sensitivity of probes, we virtually created random probes flanking HindIII cut sites and compared the enrichment in
targeted HaploSeq data from these regions to the data from regions containing true probes. We observe ~100 fold more reads from true regions (on
target, yellow) than the random regions (off target, green) and this fold-enrichment suggests high-sensitivity of our probes. b High correlation of targeted
HaploSeq and the previously published HaploSeq datasets from GM12878 cells at the MHC locus (r2 = 0.8). c An example of haplotype inconsistency in
the parent-child trio WGS data. Specifically, HapA (TGT-blue) and HapB (CAG-red) represent two haplotypes inferred from the trio dataset. Single-end
reads from targeted HaploSeq (top) and Moleculo long-fragment reads (bottom) support a case of an inter-haplotype adjacent SNP-pair (green) and
therefore raises an inconsistency with the parent-child trio haplotype inference. d Overall, ~95 % of the targeted HaploSeq reads representing
homologous-trans (h-trans) interacting SNVs are concordant with the Moleculo LFR data. e High-resolution phasing capabilities of targeted HaploSeq
method at the MHC locus. Completeness represents the collection of all heterozygous SNVs (red) within the MHC locus. Resolution represents the set
of phased or resolved heterozygous SNVs in a single haplotype structure. While we observe ~1 % error, these errors are highly concentrated in the
high variant density regions. The bottom section represents phasing of only exonic variants. f Similar figure as e) for the KIR locus
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Taken together, we present targeted HaploSeq and
demonstrate its application for targeted phasing of HLA
and KIR loci in the human genome. We believe that this
method will lead to new avenues in biomedical research
and in personalized clinical genomics.
Data access
All sequencing data have been submitted to the Gene
Expression Omnibus (GEO) database and will be publi-
cally available upon publication. Data has been made
available under the accession number GSE65726.
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Additional files
Additional file 1: Figure S1. Targeting regions around HindIII cut sites
allows complete and high-resolution haplotyping of MHC and KIR loci. a) (i)
and (ii) depict completeness and resolution at MHC locus, respectively. We
simulated reads across +/− 400 bp from HindIII cut sites in the MHC region to
study our ability to obtain complete and high-resolution haplotypes. As the
MHC region has a high-density of het. variants (a het. variance every ~300
bases), 2X sequencing coverage is enough to generate complete haplotypes,
regardless of read length. On the same lines, we obtain high-resolution seed
haplotypes at low sequencing coverage. b) (i) and (ii) depict completeness
and resolution at KIR locus respectively. On the contrary, as the KIR locus has a
lower density of variants, high sequencing coverage is required to obtain
complete haplotypes. In particular, 40 bp reads are not enough to obtain
complete phasing even at 50X coverage and therefore is omitted in the
resolution plot. Similary, even at high sequencing coverage, resolution is very
limited regardingless of read length. (TIFF 8219 kb)
Additional file 2: Figure S2. Targeted enrichment at the KIR genomic
locus. a) Genome browser shot of the ~1 Mb KIR region. The inset shows
targets near KIR3DL2 gene, depicting target regions (green) around
HindIII cut sites and repeat segments (red). We tiled 120-bp probes (blue)
at 4X density accross these non-repeat target regions. b) (i) Top Plot
demonstrates enrichment of GM12878 Targeted-HaploSeq reads at the
100 kb binned KIR locus while the bottom plot shows number of probes
used across the KIR locus. Together, these plots show a high correlation
among probes and read enrichment. (ii) Plot demonstrating sensitivity of
capture probes—the true probes capture reads ~100 fold than random
probes created virtually near HindIII cut sites (TIFF 8219 kb)
Additional file 3: Figure S3. Targeted HaploSeq data has large pool of
long insert fragments. a) Insert-size distribution of targeted Haploseq
(green) and b) HaploSeq (purple) in GM12878 LCLs. Both these datasets
have similar amount of long-insert fragments which is critical for long
range haplotyping. (TIFF 8219 kb)
Additional file 4: Figure S4. Homologous chromosomal interactions are
rare and most of them are enriched in high variant density regions of the
MHC loci. Using haplotypes indentified from the parent-trio whole genome
sequencing data, we define homologous trans (h-trans) interactions in the
Targeted Haploseq (green) and HaploSeq—from our previous publication
(purple). a) h-trans interactions are rare −< 1 % in whole genome (i), about
5–6 % in the MHC locus (ii) and <0.5 % in KIR locus (iii). While h-trans
interactions are <1 % whole-genome, we see them in significantly higher
fractions at the MHC locus (~5 %). Interestingly, majority of these are found
at regions with very high variant density (b), suggeting that the haplotype
predictions from parent-trio data at these regions could be error-prone,
which in-turn results in higher h-trans in HaploSeq datasets. (TIFF 8219 kb)
Additional file 5: Online Methods. (DOCX 149 kb)
Additional file 6: Figure S6. Targeted HaploSeq generates a single
(complete) haplotype structure across MHC/KIR locus. The performance
metric of the Targeted HaploSeq protocol, measured by completeness
(span of the haplotype bloc), resolution (fraction of het. alleles resolved),
and accuracy. While each of these metrics were defined after performing
read-based as well as population based haplotyping, seed resolution is
estimated only based on read-based haplotyping. The overall resolution
is defined as the weighted average among all alleles accross the MHC
and KIR loci together. We observe over 50 % decrease in error rate from
2.3 to 1.06 % after correcting for potential incorrect local haplotypes from
parent-trio data. (TIFF 8219 kb)
Additional file 7: Figure S7. Targeted HaploSeq generates high quality
phasing of heterozygous genes. Over 92 % of exonic het. variants are
phased at an accuracy of 99 %. (TIFF 8219 kb)
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